Fiche centre
Keimyung University Dongsan Hospital
Daegu — South Korea
Essais liés8clinical trials
VilleDaegulocalisation
PaysSouth Korealocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT06091865
Essais cliniques associés
8| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Survodutide | Maladie rénale chronique | Phase 3 | NCT06077864 | A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT) | COMPLETED |
| Selatogrel | Maladie coronarienne | Phase 3 | NCT04957719 | SOS-AMI — Selatogrel Outcome Study in Suspected Acute Myocardial Infarction | ENROLLING_BY_INVITATION |
| In-hospital staged complete revascularization | Maladie coronarienne | Non applicable | NCT07741721 | Optimal Timing of Staged Complete Revascularization in STEMI With Multivessel Disease (OPTION-STEMI2) | RECRUITING |
| Nivolumab | Cancer | Phase 3 | NCT06561386 | RELATIVITY1093 — A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1% | RECRUITING |
| Epcoritamab | SEP | Phase 2 | NCT05660967 | EPCORE DLBCL-3 — Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma | TERMINATED |
| TAR-200 | Cancer | Phase 3 | NCT06211764 | SunRISe-5 — A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG) | ACTIVE_NOT_RECRUITING |
| Odronextamab | Cancer | Phase 3 | NCT06091865 | OLYMPIA-3 — A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma | RECRUITING |
| Oxaliplatin, 5FU, leucovorin | Cancer | Phase 2 | NCT07062536 | mFOLFOX/mFOLFIRI vs. mFOLFOX in Advanced or Recurrent Biliary Tract Cancer Second-line | RECRUITING |